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a b s t r a c t
Background: Adjuvant radiotherapy (RTE) still has a fundamental role as a post-operative
treatment of locally advanced soft tissues sarcomas of the extremities. Moreover the
employment of combined modalities in locally advanced soft tissues sarcomas of the
extremities allow to maximize the chance of local cure even in difﬁcult presentation cases,
and possibly improve survival, especially in high-risk disease patients. In patients with sar-
comas of the extremities in which deﬁnitive surgery has not been radical (with positive or
“close”margins) radiotherapy can improve the results in terms of Disease Free Survival (DFS)
and, together with chemotherapy, of Overall Survival (OS). We recommend radiotherapy in
case of deep tumor location, inadequate surgicalmargins and grade 3 tumour; for positive or
“marginal (or close)” excision (that means inadequate surgery) or in selected patients with
a bad prognosis, we believe that a multidisciplinary approach can be preferable.
Introduction: Adjuvant radiotherapy (RTE) still has a fundamental role as a post-operative
treatment. In patientswith sarcomas of the extremities inwhomdeﬁnitive surgery has been
or not radical (positive or “close” margins), radiotherapy with chemotherapy can improve
the results in terms of Disease Free Survival (DFS) and Overall Survival (OS), while RTE alone
seems to improve local control.
Materials and methods: From 1/2000 to 12/2005 we treated 34 patients affected by locally
advanced sarcomas of the upper or lower extremities with radiotherapy (doses ranging
from 54 to 66Gy) and chemotherapy in 18/34 with an adjuvant scheme that consisted in
Epirubicine (120mg/m2) plus Ifosfamide (7000–9000mg/m2).
Results: Disease Free Survival (DFS) and the Overall Survival (OS) rates were 76% and 82%,
respectively. Eighteen patients developed one or more long-term side effects. Most of these
complications were mild: all patients experienced only erithema, edema, local sclerosis or
moderate pain.Conclusion: Radiotherapy has an important role as a post-operative treatment also whensurgery was non-radical.
mas of the extremity with
adjuvant chemotherapy.
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Table 1 – Example of treatment planning.120 reports of practical oncology an
1. Introduction
Soft-tissue sarcomas (STS) represent a rare andheterogeneous
group of tumours, accounting for 0.7% of all cancers.1
Soft-tissue sarcomas can occur anywhere in the body, but
most originate in an extremity (59%), the trunk (19%), the
retroperitoneum (15%), or the head and neck (9%).2
Soft-tissue sarcomas are generally classiﬁed based on
the histogenesis and/or cytomorphological features of the
tumour. The most commonly used systems are the French
grading and the National Cancer Institute grading. Both are
3-grade systems and are mainly based on histologic type and
subtype, tumour necrosis, and mitotic activity.3
The threemost important prognostic factors are grade, size
and depth of the primary tumour (relative to the superﬁcial
fascia).4
Patients with high-grade lesions, large (T2) sarcomas, non-
extremity subsite location, or deep tumour location, are
at increased risk for disease relapse and sarcoma-speciﬁc
death.5,6
Adjuvant radiotherapy (RTE) still has a fundamental role
as a post-operative treatment. In patients with sarcomas of
the extremities in whom deﬁnitive surgery has not been radi-
cal (positive or “close” margins), radiotherapy can improve the
results in terms of Disease Free Survival (DFS) and, combined
with chemotherapy, in terms of Overall Survival (OS).7–10
The purpose of this study was to determine the effect of
radiation therapy on disease free and overall survival among
patients with primary soft-tissue sarcomas of the extremities,
above all if a surgery has not been radical.
2. Materials and methods
From 1/2000 to 12/2005 we treated 34 patients affected by
locally advanced sarcomas of the upper or lower extremi-
ties. These patients were treated in the majority of cases
with a radical excision (12/34), with biopsy and radical exci-
sion (11/34) or with wide excision alone (11/34), followed by
radiotherapy with or without chemotherapy. All the exci-
sions were deﬁned as surgically radical by the surgeons that
performed them. But the histological data showed “closed”
margins (<0.5 cm) in 7 patients and positive margins in 5. No
one had evaluable distant metastasis at the time of radio-
therapy. All patients underwent radiotherapy after surgery;
18/34 patients also received chemotherapy with an adju-
vant scheme that consisted in Epirubicine (120mg/m2) plus
Ifosfamide (7000–9000mg/m2). RTE was given with ≥two 3D
conformal ﬁelds using 6Mv Photon beams or photon-electron
mixed beams and 6–15Mev electron beams as a boost with
a total dose >60Gy (ICRU) in 28 patients and less than 60Gy
(ICRU) in 6 patients (range 54–66Gy). The 12 patientswith close
or positive margins received both chemotherapy and radio-
therapy delivered at the dose of 66Gy.
An example of treatment parameters for one patient is
shown in Table 1 . Table 1a represents the ﬁrst part of treat-
ment (0–50Gy); Table 1c represents the second part of the
treatment (boost) (from 50 to 60Gy if negative margins or
64–66Gy if “close” or positive margins). Table 1b represents
reports of practical oncology and radio














the Dose Volume Histogram (DVH) of the ﬁrst part of treat-
ent (0–50Gy) for the CTV and PTV and for the bones of the
eg. Table 1d represents the Dose Volume Histogram (DVH) of
he second part of treatment (from 50 to 60Gy if negative mar-
ins or 64–66Gy if “close” or positive margins) for the CTV and
TV and for the bones of the leg. The CTV was deﬁned on the
asis of the pre-operative MRI. The PTV was represented by
he CTV plus 3 cm margins.
. Results
ll patients completed the radiotherapy course without inter-
uption. After completion of therapy, patients were followed
nitially at 4-month intervals for 2 years then subsequently bi-
nnually for 2 years, then yearly. Surveillance was important
o detect recurrences that might still be potentially curable
Fig. 1 – Disease f
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and long-term side effects. Follow-up studies included a thor-
ough clinical examination, routine chemistry, chest X-ray, and
CT scan or magnetic resonance imaging (MRI) of the region
including the primary site. With a medium follow-up of 26
months (range 12–64months), wehad 26/34 patients thatwere
free from disease. Six patients died in a period ranging from
18 to 42 months from the end of treatment due to conse-
quences of the progression of disease, two of them were in the
group with positive margins and one in the group with close
margins. Until now, one patient has had lung metastases and
only 1 has had a local recurrence. These patients have been
treated according to intern protocol of salvage chemotherapy.
As shown in Figs. 1 and 2, the Disease Free Survival (DFS) and
the Overall Survival (OS) rates were 76% and 82%, respectively.
Eighteen patients developed one or more long-term side
effects. Most of these complications were mild: all patients
experienced only a local erithema (or a different pigmenta-
tion of the skin), edema, local sclerosis or moderate pain.
Five patients had mild motion impairment, particularly on the
account of the lower extremity: difﬁculty in goingup anddown
stairs or walking and tendency to tiredness. They did not have
a signiﬁcant improvement in the ability to drive a car or be
employed.
No patients developed more serious complications than
skin necrosis, bone fractures or sciatic nerve palsy. All patients
that received chemotherapy developed haematologic toxicity:
myelosuppression with grade 3–4 leukopenia was observed
in 10 patients, grade 3–4 trombocytopenia in 3 and anemia
requiring transfusion in 5.
4. DiscussionThe employment of combined modalities in locally advanced
soft-tissue sarcomas of the extremities will be able to maxi-
mize the chance of local cure even in difﬁcult presentation,
and possibly improve survival, especially in high-risk disease.
ree survival.
survival.
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The surgical approach to soft-tissue sarcomas depends on
careful pre-operative staging with MRI or CT for lesions of
the extremities and a histologic diagnosis and assessment of
grade. In most instances, pre-operative imaging studies allow
for accurate prediction of resectability preventing the risk for
local recurrence due to poor primary resections.11
Surgical resection of sarcomas with negative surgical
margins remains the mainstay of treatment and allows ade-
quate margin of normal tissue for patients with no evidence
of metastatic disease, and for small low-grade superﬁcial
tumours in which adequate margins can be obtained. Surgery
involves resection of all gross visible and palpable tumours en
bloc, including previous biopsy scars and drain tract and large
volumes of grossly normal tissue.12–14
Optimal resection seems to be the best predictive param-
eter for a favourable outcome in term of local control in
localized STS.10
For large, deep tumours where surgical margins are likely
to be close in order to preserve important neurovascular struc-
tures and bone, the addition of radiotherapy to resection has
improved local control and increased limb salvage but with-
out affecting overall survival.15 Intuitively, decreasing local
failures and thus distant metastases would improve overall
survival, but this has not yet been proven.
A number of retrospective reports, as well as a random-
ized trial from the NCI, have demonstrated that limb-sparing
surgery plus post-operative irradiation produces local control
rates comparable to those achievedwith amputation.16,17 Five-
year local control rates of 70–90%, survival rates of 70%, and
limb-preservation rates of 85% can be expected. Combined
limb-sparing therapy and radiation therapy is currently the
standard of care for primary treatment of patients with soft-
tissue sarcomas.18 Our experience with a total DFS of 76% and
OS of 82% follows the tendency showed by these data.
Radiotherapy can be used as well as neoadjuvant treat-
ment. The ideal sequence of surgery and radiation, whether
to use pre-operative (neoadjuvant) or post-operative (adju-
vant) irradiation for local management of soft-tissue sarcoma
remains controversial on the basis of early versus late treat-
ment complications, although pre-operative radiation can
provide the best results for improved long-term function and
has been addressed in retrospective as well as in prospec-
tive randomized trials.19–22 Pre-operative irradiation has the
advantage of potentially rendering an unresectable tumour
resectable, allowing limb-salvage surgery, reducing the risk of
seeding at the time of surgery, and permitting larger radia-
tion therapy ﬁelds without interfering with wound healing.23
However, pre-operative irradiation has also several draw-
backs. They include both the inability to precisely stage
patients based on pathology due to downstaging and the
increased problems with wound healing.24,25 Since the pre-
operative treatment is burdened by an increase in morbidity
in terms of wound healing, it is deemed appropriate to apply
post-operative radiotherapy and reserve the pre-operative
procedure only for injuries initially not operable. This is, at the
moment, the reason that led us to performonly post-operative
RTE.
Unfortunately, despite major advances in surgical and
radiotherapy techniques, and signiﬁcant improvements in the
rate of local control, ≈50% of patients will ultimately developiotherapy 1 5 ( 2 0 1 0 ) 119–124
metastatic disease. Patientswithhigh-risk lesions should ben-
eﬁt from adjuvant or neoadjuvant chemotherapy.26
It is difﬁcult to assess the role of adjuvant chemotherapy,
since a number of trials, different reviews, and meta-analysis
performed in the past 20–30 years have shown conﬂicting
results as they included small numbers of patients, with dif-
ferent tumour histologies, grade and location, treated with
different drugs at different doses.27 Adjuvant chemotherapy
has been shown to reduce the risk for local relapse, dis-
tant relapse and to improve disease free survival and quality
of life. Some studies have arrived at conﬂicting conclusions
regarding the inﬂuence of adjuvant chemotherapy on overall
survival: there are overall survival beneﬁts for speciﬁc histo-
logical types, but this is a relatively small subgroup.28–31
Adjuvant doxorubicin/ifosfamide combinations may
improve relapse-free survival in carefully selected patients
and can be considered for the treatment of those with
tumour size >5 cm, deep tumour location, and high histologic
grade.32–34
Pre-operative chemotherapy should be considered for ﬁt,
high-risk patients after a discussion of the risks and poten-
tial beneﬁts. Retrospective review showed that neoadjuvant
chemotherapy was feasible and did not compromise subse-
quent treatment surgerywith orwithout radiotherapy, anddid
not increase post-operative morbidity in patients with soft-
tissue sarcomas.36–38
The speciﬁc regimens employed have evolved over the
years but generally contain both an anthracycline and ifos-
famide, their use featured by the occurrence of cardiac and
renal toxicity. Older patients, especially those with cardiac or
renal disease, are not optimal candidates for such treatment.
Despite the theoretical advantages, there is no evidence
that neoadjuvant chemotherapy is better than the adjuvant
approach in terms of DFS (Disease Free Survival), and OS
(Overall Survival), but response to neoadjuvant treatment is
a prognostic factor for local disease control.42
Consequently, treatment depends on the speciﬁc type of
sarcoma. Because sarcomas are relatively uncommon, yet
comprise a wide variety of different entities, evaluation by
oncology teams who have expertise in the ﬁeld is recom-
mended.
Our data revealed the clinical beneﬁts from chemotherapy
in combination with surgery and radiotherapy, although no
treatment-related conclusions can bemade. In fact, we cannot
conclude, with our data, that the combination of chemother-
apy and radiotherapy is the choice modality for these patients
instead of radiotherapy alone, particularly if local control is
the primary aim. But all the patients treated with chemother-
apy were classiﬁed at high risk of distant metastasis; this was
the motivation for the systemic therapy.
Radiotherapy has an important role as a post-operative
treatment, also when non-radical. It improves local control
more in patients with high-grade sarcomas of the extrem-
ity with positive or close margins.8,9 In our study we decided
to give a high dose RTE to the category of patients that we
considered at risk (12 patients totally); they received also
chemotherapy. Finally, in terms of DFS and OS we obtained a
result that is similar to results of patients treated with a really
radical surgery.Obviously, thenumber of patients thatwehave
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herapy plus chemotherapy treatment protocol can give these
nfortunate patients similar surviving chances. Our data are
n fact similar to those that can be found in literature on this
athology.
We recommend radiotherapy in case of deep tumour loca-
ion, inadequate surgical margins and grade 3 tumour; for
ositive or “marginal (or close)” excision (that means inade-
uate surgery) or in selected patients with a bad prognosis, we
elieve that a multidisciplinary approach can be preferable.
. Conclusion
urgery is the leading procedute in the treatment of soft tissue
arcomas of the extremities. Radiotherapy has an important
ole as a post-operative treatment above all when it was non
adical. It improve local control in patients with high-grade
arcomas with positive or close margins. In our experience
e decided to give a high dose RTE in this category of patients
hatwe considered at risk of local recurrence addistantmetas-
ases; they received also chemotherapy. Finally we obtained a
esult in terms of DFS and OS that is similar to those that were
reated with a really radical surgery. Obviously the number of
atients that we have treated is too small, but we believe that
treatment protocol based on high dose radiotherapy plus
hemotherapy can give to these unfortunate patients similar
urviving chances. Our data are in fact similar to those of lit-
rature for this pathology. We need further follow up in order
o conﬁrm our data.
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